Listen to this episode on:
In this episode, Brandon Li sits down with Cosmo Feilding Mellen, CEO of Beckley Psytech, to explore the groundbreaking work Beckley is doing in the world of psychedelics. Cosmo shares his journey growing up in a family immersed in psychedelic research, co-founding Beckley Psytech, and pushing the boundaries of mental health treatment with next-generation compounds like 5-MeO-DMT.
Tune in to discover why Beckley Psytech is focusing on shorter, scalable psychedelic treatments for conditions like treatment-resistant depression and substance use disorders. Cosmo explains how their innovative approach aims to make these therapies more accessible while maintaining high ethical standards, balancing cutting-edge science with compassionate care. Learn about the future of psychedelics as pharmaceutical medicines, and what it takes to develop new treatments in this rapidly evolving field.
Subscribe to Power's Newsletter
Stay ahead with a new patient recruitment insight every week.